Brief: Synaptogenix Announces Phase 2B Nih Sponsored Alzheimer's Disease Trial Update

TAO Synergies

09/06/2021 14:17

June 9 (Reuters) - Synaptogenix Inc  SNPX.O :
    * SYNAPTOGENIX ANNOUNCES PHASE 2B NIH SPONSORED ALZHEIMER'S
DISEASE TRIAL UPDATE
    * SYNAPTOGENIX INC - DATA SAFETY MONITORING BOARD CONFIRMS
BRYOSTATIN-1 SAFETY
    * SYNAPTOGENIX - INDEPENDENT DATA SAFETY MONITORING BOARD
OVERSEEING TRIAL CONVENED TO ASSESS SAFETY OF BRYOSTATIN THROUGH
INTERIM ANALYSIS
    * SYNAPTOGENIX - DSMB OVERSEEING TRIAL CONFIRMED THAT 40
ADVANCED
AD PATIENTS HAVE BEEN DOSED WITH BRYOSTATIN WITHOUT ANY
SIGNIFICANT SAFETY ISSUES

Source text for Eikon:  ID:nPndJGWva 
Further company coverage:  SNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))